{"transactions":[{"id":697160,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-04T21:22:36.000Z","date":"2026-07-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":194791,"price":3.38,"value":658393.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld to pay tax withholding obligations due on the date of settlement."}],"balance_after":168663,"source":{"system":"sec-edgar","filing":"0001193125-26-333136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000119312526333136/ownership.xml","form_type":"4"}},{"id":697159,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-04T21:22:36.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":354454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023."}],"balance_after":363454,"source":{"system":"sec-edgar","filing":"0001193125-26-333136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000119312526333136/ownership.xml","form_type":"4"}},{"id":1304306,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-13T22:30:09.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":66500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":66500,"derivative":{"underlying":"Common Stock","underlying_shares":66500},"source":{"system":"sec-edgar","filing":"0000950170-25-004923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000095017025004923/ownership.xml","form_type":"4"}},{"id":1304305,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:30:09.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 600,000 shares of common stock, which option vests with respect to 150,000 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":600000,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000950170-25-004923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000095017025004923/ownership.xml","form_type":"4"}},{"id":1354249,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-22T22:00:05.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":1015743,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 1,015,743 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 380,904 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 634,839 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":1015743,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":1015743},"source":{"system":"sec-edgar","filing":"0000950170-24-130272","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000095017024130272/ownership.xml","form_type":"4"}},{"id":1478954,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T21:00:08.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":517454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 517,454 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 129,363 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 388,091 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":517454,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":517454},"source":{"system":"sec-edgar","filing":"0000950170-24-073772","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000095017024073772/ownership.xml","form_type":"4"}},{"id":1908292,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock (right to buy)","published_at":"2023-05-02T22:49:08.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":383299,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 383,299 shares of Common Stock, which option vests with respect to 95,825 shares on May 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending May 1, 2027."}],"balance_after":383299,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":383299},"source":{"system":"sec-edgar","filing":"0001209191-23-026732","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000120919123026732/doc4.xml","form_type":"4"}},{"id":2036094,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:56:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":153600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on February 1, 2022. The option satisfied the performance criteria with respect to 153,600 shares of underlying Common Stock and these credited shares will satisfy the time-based vesting criteria with respect to 38,400 shares of Common Stock on February 1, 2023, and then with respect to 1/48th of the credited shares monthly over the three-year period ending February 1, 2026."}],"balance_after":153600,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":153600},"source":{"system":"sec-edgar","filing":"0001209191-23-006324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000120919123006324/doc4.xml","form_type":"4"}},{"id":2036093,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:56:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 300,000 shares of Common Stock, which options vests with respect to 75,000 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending February 1, 2027."}],"balance_after":300000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-23-006324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000120919123006324/doc4.xml","form_type":"4"}},{"id":2416652,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T22:38:38.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":108000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 108,000 shares of Common Stock, which option vests with respect to 27,000 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026."}],"balance_after":108000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001209191-22-006492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000120919122006492/doc4.xml","form_type":"4"}},{"id":2462445,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-21T21:05:34.000Z","date":"2021-12-20","kind":"purchase","acquired":true,"shares":2000,"price":4.48,"value":8960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were purchased in an open market transaction in accordance with the Issuer's trading policies."}],"balance_after":9000,"source":{"system":"sec-edgar","filing":"0000899243-21-049171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000089924321049171/doc4.xml","form_type":"4"}},{"id":2596193,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-19T20:05:24.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":4000,"price":6.21,"value":24840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple open market transactions in accordance with the Issuer's trading policies at prices ranging from $6.20 to $6.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001209191-21-052519","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000120919121052519/doc4.xml","form_type":"4"}},{"id":2673969,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-10T21:25:51.000Z","date":"2021-06-09","kind":"purchase","acquired":true,"shares":3000,"price":8.01,"value":24030.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports an open market purchase by the Reporting Person of shares of common stock in accordance with the Issuer's trading policies."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-21-022998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000089924321022998/doc4.xml","form_type":"4"}},{"id":3031329,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-16T00:12:21.000Z","date":"2020-09-11","kind":"grant","acquired":true,"shares":18278.14,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 18,278.14 shares of the Issuer's Series X1 Convertible Preferred Stock, one quarter of which will become fully vested and exercisable on September 11, 2021, with the remaining 13,708.605 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer."}],"balance_after":18278.14,"derivative":{"exercise_price":500,"expiration_date":"2020-09-11","underlying":"Series X1 Convertible Preferred Stock","underlying_shares":18278.14},"source":{"system":"sec-edgar","filing":"0000899243-20-025169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000089924320025169/doc4.xml","form_type":"4"}},{"id":4462334,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Restricted Stock Option","published_at":"2017-02-09T00:42:09.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-17-008914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117008914/doc4.xml","form_type":"4"}},{"id":4471923,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Stock Option","published_at":"2017-02-03T00:29:17.000Z","date":"2017-02-01","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on February 2, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":350000,"derivative":{"exercise_price":42.55,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001209191-17-007325","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117007325/doc4.xml","form_type":"4"}},{"id":4513446,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Business Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2016-12-22T21:20:12.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the time-vested portion of the reporting person's 2016 Annual Stock Option award.  The reporting person also received an option to purchase 25,000 shares of ALNY common stock that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":25000,"derivative":{"exercise_price":42.22,"expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001325812-16-000110","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581216000110/edgardoc.xml","form_type":"4"}}]}